Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers.
CYB004’s robust psychedelic effects were seen within two minutes of administration, reaching a peak at about thirteen minutes. No safety concerns were reported from the dosed group.
Part 3 (C) of the Phase 1 trial has a crossover design set to evaluate IV bolus plus infusion regimens of CYB004 in up to two cohorts. Together with completed Part B, they are expected to provide a comprehensive PK/PD model toward determining optimal dosing and formulation for following trials on the proprietary drug.
Cybin anticipates a safety …